These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34729614)

  • 1. Initial Institutional Experience with 18F-Fluciclovine PET-CT in Biochemical Recurrence of Prostate Cancer.
    Farkas AB; Green ED; Thaggard AL; Vijayakumar V; Henegan JC; Lirette ST; Nittala MR; Vijayakumar S
    South Med J; 2021 Nov; 114(11):703-707. PubMed ID: 34729614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for
    Kim EH; Siegel BA; Teoh EJ; Andriole GL;
    Urol Oncol; 2021 Jun; 39(6):365.e9-365.e16. PubMed ID: 33160848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of hormonal therapy on
    Bulbul JE; Hashem A; Grybowski D; Joyce C; Rashad E; Gabriel MS; Wagner RH; Savir-Baruch B
    Urol Oncol; 2022 Aug; 40(8):379.e9-379.e16. PubMed ID: 35738974
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Calais J; Ceci F; Eiber M; Hope TA; Hofman MS; Rischpler C; Bach-Gansmo T; Nanni C; Savir-Baruch B; Elashoff D; Grogan T; Dahlbom M; Slavik R; Gartmann J; Nguyen K; Lok V; Jadvar H; Kishan AU; Rettig MB; Reiter RE; Fendler WP; Czernin J
    Lancet Oncol; 2019 Sep; 20(9):1286-1294. PubMed ID: 31375469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Clinical Utility of
    Nakamoto R; Harrison C; Song H; Guja KE; Hatami N; Nguyen J; Moradi F; Franc BL; Aparici CM; Davidzon G; Iagaru A
    Mol Imaging Biol; 2021 Aug; 23(4):614-623. PubMed ID: 33469884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial.
    Andriole GL; Kostakoglu L; Chau A; Duan F; Mahmood U; Mankoff DA; Schuster DM; Siegel BA;
    J Urol; 2019 Feb; 201(2):322-331. PubMed ID: 30179618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-fluciclovine PET/CT detection of biochemical recurrent prostate cancer in patients with PSA levels <2.00 ng/mL.
    Garza D; Kandathil A; Xi Y; Subramaniam RM
    Nucl Med Commun; 2021 Aug; 42(8):907-913. PubMed ID: 33741863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic performance of 18F-fluciclovine PET/CT for regional lymph node metastases in patients with primary prostate cancer: a multicenter phase II clinical trial.
    Suzuki H; Jinnouchi S; Kaji Y; Kishida T; Kinoshita H; Yamaguchi S; Tobe T; Okamura T; Kawakita M; Furukawa J; Otaka A; Kakehi Y
    Jpn J Clin Oncol; 2019 Sep; 49(9):803-811. PubMed ID: 31095314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.
    Odewole OA; Tade FI; Nieh PT; Savir-Baruch B; Jani AB; Master VA; Rossi PJ; Halkar RK; Osunkoya AO; Akin-Akintayo O; Zhang C; Chen Z; Goodman MM; Schuster DM
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1773-83. PubMed ID: 27091135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is There Any Role for 18F-Fluciclovine PET/CT in the Presence of Undetectable PSA in Prostate Cancer Patients After Definitive Treatment?
    Teyateeti A; Teyateeti A; Macapinlac HA; Lu Y
    Clin Nucl Med; 2020 Sep; 45(9):672-678. PubMed ID: 32604105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world evidence of
    Friedrich NA; Gu L; Waller J; De Hoedt AM; Klaassen Z; Freedland SJ
    Prostate; 2024 Oct; 84(14):1336-1343. PubMed ID: 39031050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-Fluciclovine PET/CT Detection of Recurrent Prostate Carcinoma in Patients With Serum PSA ≤ 1 ng/mL After Definitive Primary Treatment.
    England JR; Paluch J; Ballas LK; Jadvar H
    Clin Nucl Med; 2019 Mar; 44(3):e128-e132. PubMed ID: 30589673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating appropriateness of 18F-fluciclovine PET/CT relative to standard of care imaging guidelines and the impact of ADT on positivity: a prospective study in 62 Veterans Administration patients at a single institution.
    Green A; Temsah P; Goldfarb L; Sanfolippo K; Knoche E; Muzaffar R; Osman MM
    Nucl Med Commun; 2024 Jun; 45(6):526-535. PubMed ID: 38517329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage Radiotherapy Management Decisions in Postprostatectomy Patients with Recurrent Prostate Cancer Based on
    Abiodun-Ojo OA; Jani AB; Akintayo AA; Akin-Akintayo OO; Odewole OA; Tade FI; Joshi SS; Master VA; Fielder B; Halkar RK; Zhang C; Goyal S; Goodman MM; Schuster DM
    J Nucl Med; 2021 Aug; 62(8):1089-1096. PubMed ID: 33517323
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Armstrong JM; Martin CR; Dechet C; Morton K; Evans D; Ambrose J; Maughan BL; O'Neil B; Lowrance W
    Urol Oncol; 2020 Jul; 38(7):636.e1-636.e6. PubMed ID: 32317221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorine-18-Labeled Fluciclovine PET/CT in Clinical Practice: Factors Affecting the Rate of Detection of Recurrent Prostate Cancer.
    Savir-Baruch B; Lovrec P; Solanki AA; Adams WH; Yonover PM; Gupta G; Schuster DM
    AJR Am J Roentgenol; 2019 Oct; 213(4):851-858. PubMed ID: 31216198
    [No Abstract]   [Full Text] [Related]  

  • 18. PSA and PSA Kinetics as Predictors for 18F-Fluciclovine PET/CT Positivity in Biochemically Recurrent Prostate Cancer.
    Crocerossa F; Carbonara U; Parekh J; Urdaneta A; Weprin S; Damiano R; Grob MB; Hampton LJ; Paul A; Autorino R; Cantiello F
    Urol Int; 2022; 106(9):920-927. PubMed ID: 34933313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment.
    Chen B; Bathala TK; Xu G; Teyateeti A; Chapin BF; Tang C; Tu SM; Macapinlac HA; Lu Y
    Clin Nucl Med; 2020 May; 45(5):349-355. PubMed ID: 31977495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic accuracy of 18F-fluciclovine PET/CT in primary lymph node staging of prostate cancer.
    Hoekstra RJ; Beulens A; Vrijhof EHJEJ; Wyndaele DNJ; Roef M; Brouwer LJM; Somford DM; Sedelaar M; van Basten JA
    Nucl Med Commun; 2021 May; 42(5):476-481. PubMed ID: 33323869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.